Stock market today: S&P 500 drops for fifth day as focus shifts to Powell’s speech
BOSTON—Carl L. Gordon, a director and significant shareholder of Compass Therapeutics, Inc. (NASDAQ:CMPX), recently sold a substantial portion of his holdings in the company. According to a filing with the Securities and Exchange Commission, Gordon sold 3,571,428 shares of common stock on April 9, 2025, at a price of $1.59 per share. The total value of the transaction was approximately $5.68 million. The sale comes as the stock has shown strong momentum, gaining over 16% in the past week, according to InvestingPro data.
The shares were held indirectly, as noted in the footnotes of the filing, which detail complex relationships involving OrbiMed Genesis Master Fund, L.P., OrbiMed Genesis GP LLC, and OrbiMed Advisors LLC. Despite these associations, the filing states that Gordon, along with others involved, disclaims beneficial ownership of the securities, except to the extent of any pecuniary interest. InvestingPro analysis shows the company maintains a strong balance sheet with more cash than debt and a healthy current ratio of 14.96x.
Following the sale, Gordon retains an indirect interest in 15,219,994 shares of Compass Therapeutics. The transaction leaves him with no direct ownership of the shares sold. Compass Therapeutics, headquartered in Boston, is a company focused on developing biological products, excluding diagnostic substances. With a market capitalization of $228 million and analyst price targets ranging from $6 to $32, the company faces its next earnings report on May 12, 2025. Discover more key metrics and 8 additional ProTips with InvestingPro.
In other recent news, Compass Therapeutics has announced promising results from its COMPANION-002 Phase 2/3 trial, which evaluated the combination of tovecimig with paclitaxel in treating advanced biliary tract cancer. The trial demonstrated a statistically significant improvement in overall response rate compared to paclitaxel alone, with a notable increase from 5.3% to 17.1%. Additionally, Leerink Partners upgraded Compass Therapeutics’ stock rating from Market Perform to Outperform, raising the price target to $6.00, citing a positive outlook on the company’s clinical programs. Stifel analysts maintained a Buy rating with a $10.00 price target, expressing optimism about the upcoming release of topline data from the COMPANION-002 trial. Piper Sandler initiated coverage with an Overweight rating and a $12.00 price target, emphasizing the potential of the upcoming data readout as a significant catalyst for the company’s shares. The trial’s success is anticipated to have a considerable impact on Compass Therapeutics’ future trajectory and stock performance. The ongoing developments have garnered attention from investors and industry observers, who are keenly awaiting further data releases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.